Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03759678 · ClinicalTrials.gov registry record · Phase 2
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
A Phase 2 study of Ataxia-Telangiectasia and Louis Bar Syndrome, sponsored by IntraBio.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 5
- Study locations
NCT03759678 is a Phase 2 study of Ataxia-Telangiectasia and Louis Bar Syndrome that is active but no longer recruiting, run by IntraBio. The registered enrollment target is 39 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT03759678, a Phase 2 study of Ataxia-Telangiectasia and Louis Bar Syndrome, is active but no longer recruiting, sponsored by IntraBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T). There are two phases to this study: the Parent Study, and the Extension Phase. The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of A-T. The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of A-T.
Conditions Studied
Interventions
- DRUG IB1001
Study Locations (5)
Other
- University of Giessen - Giessen
- Ludwig Maximilian University of Munich - München
California
- University of California - Los Angeles - Los Angeles
Spain
- Hospital Universitario La Paz - Madrid
Cambridgeshire
- Royal Papworth Hospital NHS Foundation Trust - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-01-08 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03759678
The ClinicalTrials.gov registry entry for NCT03759678 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IntraBio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ataxia-Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which IB1001 is the first listed.
NCT03759678 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Spain.
Frequently Asked Questions
What is clinical trial NCT03759678 about?
NCT03759678 is a clinical study titled "N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)". This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T). There are two phases to this study: the Parent Study, and the Extension Phase. The P...
What is the current status of trial NCT03759678?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2020-01-08. Estimated completion is 2025-07-01.
What conditions does trial NCT03759678 study?
This clinical trial studies the following conditions: Ataxia-Telangiectasia, Louis Bar Syndrome.
What interventions are being tested in trial NCT03759678?
The interventions under investigation include: IB1001 (DRUG).
Who is sponsoring clinical trial NCT03759678?
This trial is sponsored by IntraBio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03759678 being conducted?
This trial has 5 study locations across California, Spain, Cambridgeshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ataxia-Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.